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A B S T R A C T
The accelerated blood clearance (ABC) phenomenon which is induced by repeated injection
of poly (ethylene glycol) (PEG)-coated colloidal carriers gives clinical challenge to the promising
drug delivery system. It is necessary to decrease this unexpected immunological response.
A novel 4-arm poly (ethylene glycol-5000)4-cholesteryl methyl amide (4-arm PEG5000-CHMA)
has been synthesized.The structure of 4-arm PEG5000-CHMA was confirmed by IR and 1H-NMR
spectrum.The pharmacokinetics of the tocopheryl nicotinate (TN)-loaded nanoemulsionsmodi-
fied with 4-arm PEG5000-CHMA or/and 1, 2-distearoyl-Sn-glycero-3-phosphoethanolamine-n-
[methoxy(poly-ethyleneglycol)-2000] (mPEG2000-DSPE) have been studied. Furthermore, the ABC
phenomenon has been detailed investigated in rats by TN-loaded nanoemulsions modified
with 4-arm PEG5000-CHMA and mPEG2000-DSPE (CPNE). The plasma levels of TN and anti-PEG
IgM antibodywere determined byHPLC and ELISA, respectively.The circulation time of the CPNEs
were comparable to the mPEG2000-DSPE coated nanoemulsions. Moreover, the ABC phenom-
enon can be decreased by CPNEs.This study designs amethod to decrease theABC phenomenon
and develops a clinical promising nanoemulsion for therapeutic or imaging purpose.
© 2017 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
The accelerated blood clearance (ABC) phenomenon, an un-
expected immunological response that repeated administrated
of PEGylated liposomes in the same animal with certain
intervals will lead to a reduction in the circulation time and
an increase in hepatic and splenic accumulation, has been
extensively observed and is attracting more attention [1–5].
B cells, which are in the margin of spleen endowed with
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potent effector functions, are extremely required for the
induction of ABC phenomenon through producing IgM. The
antibody induced by the first dose of nanoparticles which
acts as an TI-2 antigen in the induction phase, can combine
with the second dose of PEGylated nanoparticles to activate
the complement, leading to the opsonization of C3 and then
accelerate the clearance of the second dose by the uptake of
mononuclear phagocyte system (MPS) in the effectuation
phase [6–8].
This phenomenon can also be induced by many other PEG-
conjugated substances/PEGylated nanocarriers, such as
PEGylated nanoemulsions [9], PEGylated nanoparticles [10],
PEGylated micelles [11], PEGylated proteins [12], and de-
crease therapeutic efficacy [13].Therefore, avoiding or alleviating
the ABC phenomenon is very important and valuable not only
for scientific research but also for the applicability of drug de-
livery system.
Over the past few decades, some alternative polymers
have been reported to circumvent the ABC phenomenon. In
the year of 2010, Tsutomu Ishihara demonstrated that
nanoparticles covered with poly(N-vinyl-2-pyrrolidone), poly(4-
acryloylmorpholine), or poly(N,N-dimethylacrylamide) did not
induce the ABC phenomenon. When focused on the pharma-
cokinetics of these nanoparticles, the clearance value of
PEGylated nanoparticle (3.7 ml/h/kg) is significantly smaller
than those of nanoparticles covered with poly(N-vinyl-2-
pyrrolidone) (25.7 ml/h/kg), poly(4-acryloylmorpholine) (19.0 ml/
h/kg), or poly(N,N-dimethylacrylamide) (14.1ml/h/kg), respectively
[14]. In the year of 2013, Amr S. Abu Lila proposed that the ABC
phenomenon was not induced by liposome modified with
polyglycerol (PG) upon repeated injection procedure in rats.
However, the AUC0~24 h (303.7 ± 209.2 %Dose·h/ml) of PEGylated
liposome is larger than PG coated liposomes (152.4 ± 29 %Dose·h/
ml) [15]. Obviously, one of the drawbacks in using these
proposed alternative polymers is the loss of the long circula-
tion character of nanoparticles, which is essential for clinical
applications [16].
We are here to discuss a method with mixed PEGylated sur-
factant modifying system in the field of attenuating the ABC
phenomenon. In our works,we covered the nanoemulsions with
linear PEG (mPEG2000-DSPE) and branched PEG (4-arm PEG5000-
CHMA) in different ratio. This method can keep the long-
circulating character and decrease the immunogenicity of
PEGylated nanocarriers.
The novel branched PEG material, 4-arm PEG5000-CHMA,
has been synthesized and it features a complex structure
comprising four long PEG chains. Each four chains have a
total of 128 OCH2CH2 subunits in average value. The branched
PEG material has a structural characteristic of cross-linking.
Interestingly, the ABC phenomenon would be alleviated by
nanoemulsions modified with mPEG2000-DSPE and PEG5000-
CHMA. Moreover, these CPNEs also showed a longer half-life
character, resulting in a potential accumulation in the inflam-
matory and tumorous lesion by the enhanced permeability
and retention effect [17]. From the results of ELISA, we
proposed that CPNEs disturb the secretion of antibody. In
addition, 4-arm PEG5000-CHMA decreases the following
antibody binding. Then, the ABC phenomenon was de-
creased. Finally, we find a method to decrease the ABC
phenomenon.
2. Materials and methods
2.1. Materials
4-arm PEG5000 (JenKem Technology, China); cholesterol
chloroformate (CHMA,Acros Organics, USA); triethylamine (TEA,
Tianjin Bodi Chemistry, China); dichloromethane (DCM,
Zhengxin high-tech research institute, China); tocopheryl nico-
tinate (TN, Northeast Pharmaceutical Group, China); medium-
chain triglycerides (MCT, Beiya Medicated Oil, China); injectable
soybean lecithin S75 (S75, Lipoid GmbH, Germany); mPEG2000-
DSPE (Genzyme Corporation, USA); 50% (m/v) glucose solution
(Shandong Yuwang Industry, China).
2.2. Synthesis of 4-arm PEG5000-CHMA
The 4-arm PEG5000-CHMAwas synthesized using 4-arm PEG5000
and cholesterol CHMA, as starting materials and TEA as acid
binding agent. The related accompanying reactions are out-
lined in Fig. 1. Solution A: 2 mmol TEA and 20 ml CHMA were
dissolved in DCM. Solution B: 0.2 mmol 4-arm PEG5000 was dis-
solved in 10ml DCM. SolutionAwas added dropwise to Solution
B under ice bath with gentle stirring for 30 min. Then put the
mixture at room temperature to react for 24 h. After that, the
mixture was dried by rotary evaporation and extracted by DCM
three times.The resulting mixture was washed with ice water,
hydrochloric acid (0.8 mM) and NaCl saturated solution three
times separately to remove TEA.The organic layer was evapo-
rated and the product was precipitated again using cold ethyl
ether. Finally, 4-arm PEG5000-CHMA was analyzed by 1H NMR
(Bruker 600-MHz) and FT-IR (Bruker IFS 55). For the analyzation
of 1H NMR, final material needs solute into CDCl3. For the
analyzation of FT-IR, the final material needs to be mixed with
potassium bromide and press into tablet.
2.3. Preparation of PEGylated nanoemulsions
The oil phase containing TN, MCT, S75, mPEG2000-DSPE and/or
4-arm PEG5000-CHMA (Table 1) were dissolved under 55 °C.The
water phase (sterile water for injection) which was kept in the
same temperature was dropped into that oil phase quickly while
stirring. Agitation was held for 10 min in 55 °C water bath to
obtain the primary emulsions. The final emulsion was ob-
tained by using a laboratory ultrasonic cell pulverizer (JY92-
II, Ningbo Scientz Biotechnology. Zhejiang, China) at 200 W for
2 min and at 400 W for 6 min.The emulsions were sized by ex-
trusion through polycarbonate membranes with a pore size
measuring 0.22 μm.The final emulsion was adjusted to an iso-
tonic level by using 50% (m/v) glucose solution.The particle size
distribution was estimated by the dynamic light scattering
method using the Submicron Particle Sizer (Nicomp 380™; Par-
ticle Sizing Systems, Inc., Santa Barbara CA, USA). Using the
same method, the conventional nanoemulsions, which omit
the mPEG2000-DSPE and/or 4-arm PEG5000-CHMA in the oil phase,
was prepared.
The following are the abbreviations about PEGylated
nanoemulsions: P10NE-1 (2), the first (second) injection of
nanoemulsions modified with 10 mol% mPEG2000-DSPE; C5NE-1
(2), the first (second) injection of nanoemulsions modified with
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5 mol% 4-arm PEG5000-CHMA; C10NE-1 (2), the first (second) in-
jection of nanoemulsions modified with 10 mol% 4-arm PEG5000-
CHMA; C5P5NE-1 (2), the first (second) injection of
nanoemulsions decorated with 5mol% 4-arm PEG5000-CHMA and
5 mol% mPEG2000-DSPE; P10C5NE-1 (2), the first (second) injec-
tion of nanoemulsions decorated with 5 mol% 4-arm PEG5000-
CHMA and 10 mol% mPEG2000-DSPE.
2.4. Biodistribution and pharmacokinetics of PEGylated
nanoemulsions
The maleWistar rats weighing 180~200 g were purchased from
the Experimental Animal Center of Shenyang Pharmaceuti-
cal University (Liaoning, China).All animal care and experiments
were carried out according to the guidelines of the Animal
Welfare Committee of Shenyang Pharmaceutical University. In
our pre-stage work, we confirm that PEGlylated nanoemulsions
would induce the strongest ABC phenomenon at a dose of
5 μmol phospholipid/kg which is larger than PEGylated lipo-
some (0.001 μmol phospholipid/kg) (data never given here).
For the first injection, nanoemulsions we prepared, at doses
of 5 μmol phospholipid/kg, were injected via the femoral vein.
Control group received 5% (m/v) glucose solution instead of
PEGylated nanoemulsions as following schemes (Table 2). For
the second injection, corresponding nanoemulsions were in-
jected intravenously via the femoral vein at a dose of 5 μmol
Fig. 1 – Synthesis and characterization of 4-arm PEG5000-CHMA, n = 32. (A) Synthesis of 4-arm PEG5000-CHMA. (B) 1H NMR
spectrum of 4-arm PEG5000-CHAM. (C) FT-IR spectrum of PEG, CHMC, 4-arm PEG5000-CHMA.
Table 1 – The composition of nanoemulsions.
Nanoemulsions Composition
P10NE TN/MCT/S75/mPEG2000-DSPE (2.2/10.8/2.5/1.0,w/w/w/w)
C5NE TN/MCT/S75/4-arm PEG5000-CHMA (2.0/10.0/2.5/1.0,w/w/w/w)
C10NE TN/MCT/S75/4-arm PEG5000-CHMA (1.0/5.0/1.2/1,w/w/w/w)
C5P5NE TN/MCT/S75/4-arm PEG5000-CHMA/mPEG2000-DSPE (4.4/21.7/5.3/1.0/2.2,w/w/w/w/w)
P10C5NE TN/MCT/S75/4-arm PEG5000-CHMA/mPEG2000-DSPE (2.4/11.9/2.7/1.0/1.1,w/w/w/w/w)
Conventional nanoemulsions TN/MCT/S75 (1.0/5.0/2.1,w/w/w)
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phospholipid/kg.The injection interval was 7 d.At selected post-
injection time points (0.083, 0.25, 0.5, 1, 2 and 4 h), blood was
sampled through eye marginal vein.The liver and spleen were
removed 4 h after the last blood sample was withdrawn. The
plasma samples and tissue samples were treated as follows:
100 μl of the plasma samples or homogenates (equivalent to
0.5 g tissue) weremixed withmethanol (100 μl), an internal stan-
dard (100 μl), tocopheryl acetate (100 μg/ml) and n-hexane
(600 μl). The entire mixture was vortexed for 5 min and cen-
trifuged at 10,000 rpm for 10 min.The supernatant (500 μl) was
dried using a CentriVap® Centrifugal Vacuum Concentrator
(Labconco Corporation, Kansas City, USA) and dissolved in the
mobile phase (100 μl). The resulting mixture was vortexed for
1 min and centrifuged at 10,000 rpm for 10 min.The superna-
tant (20 μl) was collected and used for analysis by high
performance liquid chromatography (HPLC) method using a
P230 pump and a UV230 UV/Vis Detector (Da Lian Elite Ana-
lytical Instruments Co., Ltd., China) composed of a Hypersil BDS
C18 column (200 mm × 4.6 mm) containing particles measur-
ing 5 μm in diameter at 30 °C. The ultraviolet wavelength was
264 nm.The mobile phase was methanol/isopropanol (80 : 20,
v/v) at a flow rate of 1 ml/min.
2.5. The calculation of ABC index
In order to quantitatively evaluate the degree of this phenom-
enon, ABC index(0–∞), a scientific and simple concept, was
proposed. In our study, the ABC index in 4 h could stand for
the extent of ABC phenomenon efficiently, because the second
dose was almost cleared from the circulation in 4 h. The cal-
culation function: ABC index(0–4h) = AUC(0–4 h) of the second
dose/AUC(0–4 h) of the control dose. The ABC indexes of three
preparations are presented in Table 3.
2.6. ELISA for detecting the anti-PEG IgM
Before the second injection, the blood samples were col-
lected. The serum was gained after standing 2 h by
centrifugation (4000 rpm, 10 min).The content of anti-PEG IgM
in the serum was detected by ELISA [9]. Experimental proce-
dure was as follows: 50 μl of mPEG2000-DSPE ethanol solution
was added (content 0.56 mg/ml mPEG2000-DSPE) into a 96-
well plate (USA, Corning), then dried under room temperature.
The plate was blocked with 100 μl of Tris (USA, Sigma-Aldrich)-
buffered saline (pH 8.0) containing 1% BSA (Bovine Serum
Albumin, Korea, Biosharp).After incubating for 1 h at room tem-
perature, the plate was washed three times with wash solution
that is tris-buffered saline (pH 8.0) containing 0.05%Tween 20
(USA, Sigma-Aldrich). Serum samples was diluted (100 μl, 1:100,
v/v) by the diluted solution (tris-buffered saline contained 1%
of BSA and 0.05% ofTween 20, pH 8.0) and added to the 96 wells.
After 1 h incubation, five times washing was required. Then
horseradish peroxidase conjugated rabbit anti-rat IgM (China,
Beijing Biosynthesis Biotechnology Co., Ltd) (100 μl, 1 μg/ml) was
added into each well and incubated in room temperature for
1 h, then washed five times. 1 mg/ml of O-phenylendiamine
(USA, Sigma-Aldrich) solution (solvent was Phosphoric-citric
acid buffer, pH 5.0) was added into each well. After incubat-
ing for 15 min, the reaction was stopped by adding 100 μl of
1 mol/l H2SO4. The absorbance was measured at 490 nm and
630 nm by a microplate reader (UK, Bio-Rad Laboratories Ltd.,
Hertfordshire).
2.7. Theoretical calculations
The data are presented as the mean ± standard deviation.The
statistical analysis was performed using Student’s t-test with
SPSS 16.0 (SPSS Inc., USA) software. The bond lengths and the
bond angles are calculated by ChemBio3D Ultra 14.0
(CambridgeSoft Inc., USA).
Table 2 – The injection scheme of the PEGylated
nanoemulsions.
Group The first
treatment (5 μmol
phospholipids/kg)
The second
treatment (5 μmol
phospholipids/kg)
1 5% glucose solution Conventional emulsion
2 5% glucose solution C5NE
3 5% glucose solution C10NE
4 5% glucose solution P10NE
5 5% glucose solution C5P5NE
6 5% glucose solution C5P10NE
7 P10NE P10NE
8 C5P5NE C5P5NE
9 C5P10NE C5P10NE
Table 3 – The main pharmacokinetic parameters of the injected nanoemulsions in rats (n = 3).
Injected dose AUC(0–∞) (mg/l/h) ABC index
AUC(0–4 h) (mg/l/h)
CL (l·h/kg) T1/2z (h) MRT(0–∞) (h) ABC index(0–4 h)
Conventional emulsion 16.179 ± 0.933 10.934 ± 1.040 1.236 ± 0.263 0.053 ± 0.002 0.057 ± 0.013
C5NE 30.681 ± 1.203 30.680 ± 2.983 0.652 ± 0.047 0.287 ± 0.001 0.315 ± 0.005
C10NE 108.094 ± 6.529 106.055 ± 7.973 0.185 ± 0.016 0.695 ± 0.033 0.899 ± 0.023
P10NE 0.16 ± 0.01
First injection 440.832 ± 9.770 230.347 ± 11.670 0.045 ± 0.004 3.588 ± 0.174 5.260 ± 0.094
Second injection 37.471 ± 2.043 36.531 ± 3.508 0.534 ± 0.033 0.781 ± 0.081 0.977 ± 0.003
C5P5NE 0.35 ± 0.06
First injection 416.342 ± 9.331 215.748 ± 10.334 0.048 ± 0.007 3.676 ± 0.142 5.363 ± 0.079
Second injection 120.094 ± 8.748 74.933 ± 5.247 0.167 ± 0.052 3.223 ± 0.119 4.124 ± 0.082
C5P10NE 0.61 ± 0.15
First injection 583.327 ± 13.579 220.228 ± 12.376 0.034 ± 0.001 5.996 ± 0.190 8.540 ± 0.130
Second injection 248.795 ± 11.430 133.327 ± 7.893 0.080 ± 0.002 3.765 ± 0.163 5.245 ± 0.127
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3. Results and discussion
3.1. The structure confirmation of 4-arm PEG5000-CHMA
The structure of 4-arm PEG5000-CHMA was confirmed by 1H-
NMR and IR, the results are shown in Fig. 1.The atomic numbers
of 4-arm PEG5000-CHMA are shown in Fig. 2. 1H-NMR (CDCl3, δ
ppm): 7.266 is the solvent peak of CDCl3; 0.675 (s, 3H, H-18);
0.854, 0.873 (d, 6H, H-26, 27); 0.902, 0.924 (d, 3H, H-21); 1.007 (s,
3H, H-21); 2.338 (br.d, 2H, H-4); 3.644 (m, 126H, H-b); 5.164 (m,
H, H-a); 5.360 (m, 1H, H-6). In 1H-NMR spectrum, a broad peak
in δ 3.644 ppm is the most obvious characteristic signal which
stands for -(CH2CH2O)32-. The rest of each peak is similar with
the 1H-NMR (CDCl3) message of cholesterol methyl chloride.
In addition, the connection of 4-arm PEG5000 to CHMA was
also verified with FT-IR spectroscopy by the presence of car-
bonyl stretching bands (at around 1719 cm−1) in amino linkage
and the carbonyl stretching vibration peak (at 1775 cm−1) of
CHMA disappeared. Each arm of 4-arm PEG5000 links with one
CHMA. We set the peak integral of methyl protons (12 alto-
gether) in all four cholesterol as 3, therefore the integral for
broad peak which presents four (CH2CH2O)32 groups of PEG
chain in 4-arm PEG5000-CHMA could be 126. The other peaks
are similar to CHMA. These results indicate that the 4-arm
PEG5000-CHMA has been successfully synthesized.Then we pre-
pared nanoemulsions using the 4-arm PEG5000-CHMA or/and
mPEG2000-DSPE (Fig. 3).
3.2. The characterization of nanoemulsions
The mean diameters of nanoemulsions are range from 120 nm
to 230 nm (Table 4). Moreover, the coefficient of variation (C.V.)
value of all the formulations which expressed the particle size
distribution ranges from 0.318 to 0.428. Table 4 also reveals that
all nanoemulsions are negatively charged because under physi-
ological pH values, one mPEG2000-DSPE and one S75 molecule
carries one negative charge while 4-arm PEG5000-CHMA is elec-
tric neutrality. Generally, nanoemulsions which carry more
mPEG2000-DSPE polymer are more negatively charged and the
shield by 4-arm PEG5000 on the surface of nanoemulsions neu-
tralizes the zeta-potential of nanoemulsions. Finally, we confirm
that mPEG2000-DSPE and 4-arm PEG5000-CHMA can insert into
the surface of nanoemulsions.
Fig. 2 – The atomic number of 4-arm PEG5000-CHMA.
Fig. 3 – (A, B) The structural chemical formulae of the 4-arm PEG5000-CHMA and mPEG2000-DSPE. (C, D) Schematic
presentation of the CPNEs and PNEs.
Table 4 – The characterization of nanoemulsions.
Formulations Mean
diameter (nm)
C.V. Zeta
potential (mV)
Conventional
emulsions
230.2 ± 6.1 0.318 ± 0.012 −15.50 ± 3.90
P10NE 119.4 ± 4.2 0.388 ± 0.007 −30.82 ± 1.77
C5NE 207.4 ± 5.7 0.374 ± 0.008 −7.59 ± 1.37
C10NE 124.2 ± 4.8 0.330 ± 0.013 −5.64 ± 3.55
C5P5NE 135.2 ± 3.2 0.428 ± 0.011 −17.54 ± 5.22
C5P10NE 113.6 ± 6.6 0.390 ± 0.008 −29.67 ± 1.09
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3.3. Pharmacokinetics of the PEGylated nanoemulsions
in rats
When we prepared nanoemulsions coated with 4-arm PEG5000-
CHMA only (CNE), the lifetime (MRT(0–∞), 0.315 ± 0.005 h (C5NE),
0.899 ± 0.023 h (C10NE)) in circulation is longer than that of the
conventional emulsions (MRT(0–∞), 0.057 ± 0.013 h), especially
before 1 h after the injection (Fig. 4). But, compared with
nanoemulsions coated with mPEG2000-DSPE only (PNE), the CNE
cannot keep an relatively high level in circulation like PNE
(MRT(0–∞), 5.260 ± 0.094 h (P10NE)).That means the 4-arm PEG5000-
CHMA cannot perfectly protect the nanoemulsions in a
persistent state.When modifying the nanoemulsions with the
4-arm PEG5000-CHMA and PEG2000-DSPE, themixed PEGylated sur-
factant modifying system, the circulation time of
nanoemulsions was prolonged by forming an stable hy-
drated layer (MRT(0–∞), 5.363 ± 0.079 h (C5P5NE), 8.540 ± 0.130 h
(C5P10NE)). Hence, the circulation time of P10NE,C5P5NE,C5P10NE
was further prolonged.Moreover, It has also been proposed that
the ABC phenomenon have association with circulation time
[16,18]. Hence, prepare the different polymer modify formu-
lations in similar level in circulation time is also basic to
compare the decrease extent of ABC phenomenon scientifically.
3.4. ABC phenomenon of the PEGylated nanoemulsions
in rats
Over the past decades, several creative approaches have been
reported to circumvent the ABC phenomenon, such as chang-
ing the physicochemical properties, ameliorating the
administration regimen, or finding other alternative polymers.
Changing the physicochemical properties: PEGyalted
nanoparticles in optimal PEG modify density elicit a maximal
ABC phenomenon,while, at either lower or higher surface density
of PEG, theABC phenomenon is reduced.The optimal PEGmodify
density value will change a lot between different type of
nanoparticles. For example, Ishida reported the optimal PEG
modify density of PEGylated liposome is 5 mol% [19]. Zhao dem-
onstrated that solid lipid nanoparticles (SLNs) containing 10mol%
PEG produced a higher elimination rate [10]. In addition,
PEGylated nanoparticles in lower size can decrease even evade
the ABC phenomenon. Koide demonstrated that the ABC phe-
nomenon cannot be induced in the profile of repeated injection
of PEG-pAsp(pentyl) micelles (33.6 nm) [20]. Kaminskas re-
ported repeated injected PEG2000-DSPE micelles (18 nm) also
cannot induce the ABC phenomenon [21]. Based on these ex-
periences, we can choose the most reasonable type of
nanoparticle for clinical use. Obviously, these methods are not
enough to solve the ABC phenomenon of various nanoparticles.
Ameliorating the administration regimen:TheABC phenom-
enon can be circumvented by increasing the injection dose for
the nanoparticles which modified with materials that have a
higher toxicity dose for intravenous injection.As reported, with
intravenous injection of 150 mg Lactosome/kg into rat, no ABC
phenomenon was found [22]. Similarly, the liposome modified
with PEGylated hemoglobin (Hb), at the dose of 1400 mg Hb/
kg,ABC phenomenon disappeared [23]. In addition, inducing the
strongest intensity of ABC phenomenon also needs an appro-
priate time interval between the first and the second injection,
such as the optimal time interval of mice [24], rat [25], and beagle
dogs [10] was 10, 5, and 7 d. When changing the injection in-
terval, the ABC phenomenon can be decreased. Moreover,
micelles used alternatively with liposome can also circum-
vent the ABC phenomenon [21]. Those methods could also
circumvent a part of nanoparticles’ ABC phenomenon. However,
we need to rethink about the influence of the curative effect by
ameliorating the administration regimen.
Finding other alternative polymers: As mentioned earlier,
poly(N-vinyl-2-pyrrolidone), poly(4-acryloylmorpholine), or
poly(N,N-dimethylacrylamide) and polyglycerol (PG) can de-
crease the ABC phenomenon, although scarify a certain degree
of circulation time [14,15]. In 2015, Li reported that
Poly(carboxybetaine) can be a newmaterial that do not induce
the ABC phenomenon, but the article never study the ABC phe-
nomenon under different injection dose [26]. In 2016, Zhang
studied that hyaluronic acid can also circumvent the ABC phe-
nomenon at the dose of 0.1 and 5 μmol lipid/kg [27].These new
materials all made important progress in the area of eliminating
the ABC phenomenon. It is the most difficult but highly ef-
fective method to solve these problems. Reviewing the progress
Fig. 4 – (A) The blood clearance profile of PEGylated nanoemulsions in rats. Rats were administrated with PEGylated
emulsions at a dose of 5 μmol phospholipids/kg. Data are shown as mean ± SD, n = 3. (B) Hepatic and splenic accumulations
4 h after i.v. injection of the test dose of PEGylated nanoemulsions. Data are shown as mean ± SD, n = 3.
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we had achieved, we found that a mixed modifier method,
which also had the chance to decrease or even remove the ABC
phenomenon, was never studied at all. Our work aimed to give
an idea that the materials we had can give consideration of
both sides; lower immunology and excellent stealth charac-
ters, by combining with other modifier methods.
We chose P10NE, C5P5NE and C5P10NE which are in the similar
level in circulation lifetime to study whether 4-arm PEG5000-
DSPE is helpful to weaken the ABC phenomenon. Rats were
treated with P10NE, C5P5NE and C5P10NE (5 μmol phospholipids/kg)
as the first dose. Set the dose interval as 7 d, the rats were in-
jected with P10NE, C5P5NE and C5P10NE (5 μmol phospholipids/kg)
as the second dose. Table 1 shows the treatment schemes. As
expected, repeated injection with P10NE, triggered the rapid
clearance of the second dose of P10NE from circulation (Fig. 5A)
and increased uptake by the liver and spleen (Fig. 5B).
(P10NE: ABCindex (0–4 h) = 0.16 ± 0.01). But from Table 3, the ABC
phenomenon is further decreased by CPNEs (C5P5NE:
ABCindex (0–4 h) = 0.35 ± 0.06; C5P10NE: ABCindex (0–4 h) = 0.61 ± 0.15). In
addition, although the nanoemulsions in the similar circula-
tion time, theABC phenomenon induced was in different extent
(P10NE > C5P5NE > C5P10NE).
3.5. Production of anti-PEG IgM
Previous studies suggest that anti-PEG IgM production levels
have a positive correlation with ABC phenomenon. ELISA was
used to detect the anti-PEG IgM levels. In this study, ELISA was
also used to study the combination ability of anti-PEG IgM to
different antigens using a 96 wells plates coated with two an-
tigens (4-arm PEG5000-CHMA or mPEG2000-DSPE). The antibody
combination of anti-PEG IgM is important for following the
complement activation and themononuclear phagocyte system
uptake. As shown in Fig. 6, PEGylated nanoemulsions induced
the production of substantial amounts of anti-PEG IgM. The
order of antibody level is, C5P5NE > P10NE > C5P10NE. Interest-
ingly, the extent of the ABC phenomenon is not completely
consistent with antibody level. Moreover, the antibody was
easier to combine with mPEG2000-DSPE than 4-arm PEG5000-
CHMA group for the higher OD value in the covered mPEG2000-
DSPE group than the covered 4-arm PEG5000-CHMA group.That
means except antibody level, antibody combination withmodify
polymers also play an important role in the induction of the
ABC phenomenon.When the antibody in a similar level such
as C5P5NE, P10NE, the antibody combination has a relation-
ship with the extent of the ABC phenomenon. Because the
antibody prefers to combine with the PEG2000-DSPE, theABC phe-
nomenon of P10NE was stronger than C5P5NE group. In this study,
we proposed covering up all the terminal group of 4-arm PEG5000
with cholesterol having the chance to circumvent the ABC phe-
nomenon by decreasing the antibody binding.
As reported [28], star shaped PEG chains, which provide a
steric stabilization, reduce complement activation of
nanoparticles. Hence, although the antibody produced by C5P5NE
is more than P10NE group, the ABC phenomenon of P10NE is
stronger than C5P5NE group for the reason of having a higher
level of complement activation. In addition, the complement
activation needs the antibody IgM stay in mushroom confor-
mation [29].We assumed that the conformations of surface layer
of emulsions become complicated in the condition of blend-
ing different structure of PEG in the formulation. Because of
the relatively complicated transformation in conformation, the
recognition of anti-PEG antibody would be difficult to stay
mushroom conformation on the surface of nanoemulsions.
Then the complement activation decreased.Therefore, we con-
sidered that the antibody level and following antibody
combination are both important for the induction of ABC phe-
nomenon.That is to say,mixed PEGylated surfactant modifying
system can decrease theABC phenomenon and will direct more
promising colloidal drug carriers in the future.
4. Conclusion
In summary, a novel material, 4-arm PEG5000-CHMA, has been
synthesized successfully and the nanoemulsions modified with
4-arm PEG5000-CHMA and/or mPEG2000-DSPE has been prepared.
Fig. 5 – (A) The blood clearance profile of P10NE, C5P5NE and C5P10NE in rats. Rats were pretreated with P10NE, C5P5NE and
C5P10NE (5 μmol phospholipid/kg) or 5% glucose solution, at 7 d post-first injection, all groups were repeated administrated
with P10NE, C5P5NE and C5P10NE separately at a dose of 5 μmol phospholipids/kg. Data are shown as mean ± SD, n = 3. (B)
Hepatic and splenic accumulations 4 h after i.v. injection of the test dose. Data are shown as mean ± SD, n = 3.
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Furthermore, the pharmacokinetic character and the ABC phe-
nomenon of PEGylated nanoemulsions have been detailed
investigated. Our researches suggest that the circulation time
is prolonged and the ABC phenomenon can be decreased at the
same time by nanoemulsions modified with 4-arm PEG5000-
CHMA and mPEG2000-DSPE. We propose that the ABC
phenomenon is decreased by the antibody secretion and the
further antibody combination. In this work,mixed PEGylated sur-
factant modifying system can reach the aim of the decrease of
ABC phenomenon as well as an ideal pharmacokinetic char-
acter. Thus, nanoemulsions with 4-arm PEG5000-CHMA and
mPEG2000-DSPE have chance to be a promising nanocarrier for
clinical use.
Acknowledgments
This research was supported by the National Natural Science
Foundation of China (Grant No. 81072602, Grant No. 81373334).
R E F E R E N C E S
[1] Dams ET, Laverman P, Oyen WJ, et al. Accelerated blood
clearance and altered biodistribution of repeated injections
of sterically stabilized liposomes. J Pharmacol Exp Ther
2000;292:107–1079.
[2] Ishida T, Maeda R, Ichihara M, et al. Accelerated clearance of
PEGylated liposomes in rats after repeated injections. J
Control Release 2003;88:35–42.
[3] Ishida T, Masuda K, Ichikawa T, et al. Accelerated clearance
of a second injection of PEGylated liposomes in mice. Int J
Pharm 2003;255:167–174.
[4] Ishida T, Atobe K, Wang X, et al. Accelerated blood clearance
of PEGylated liposomes upon repeated injections: effect of
doxorubicin-encapsulation and high-dose first injection. J
Control Release 2006;115:251–258.
[5] Xu H, Ye F, Hu M, et al. Influence of phospholipid types and
animal models on the accelerated blood clearance
phenomenon of PEGylated liposomes upon repeated
injection. Drug Deliv 2015;22:598–607.
[6] Ishida T, Kashima S, Kiwada H. The contribution of
phagocytic activity of liver macrophages to the accelerated
blood clearance (ABC) phenomenon of PEGylated liposomes
in rats. J Control Release 2008;126:162–165.
[7] Ishida T, Wang X, Shimizu T, et al. PEGylated liposomes
elicit an anti-PEG IgM response in a T cell-independent
manner. J Control Release 2007;122:349–355.
[8] Wang X, Ishida T, Kiwada H. Anti-PEG IgM elicited by
injection of liposomes is involved in the enhanced blood
clearance of a subsequent dose of PEGylated liposomes. J
Control Release 2007;119:236–244.
[9] Wang L, Wang C, Jiao J, et al. Tolerance-like innate immunity
and spleen injury: a novel discovery via the weekly
administrations and consecutive injections of PEGylated
emulsions. Int J Nanomedicine 2014;9:3645–3657.
[10] Zhao Y, Wang L, Yan M, et al. Repeated injection of
PEGylated solid lipid nanoparticles induces accelerated
blood clearance in mice and beagles. Int J Nanomedicine
2012;7:2891–2900.
[11] Koide H, Asai T, Kato H, et al. Size-dependent induction of
accelerated blood clearance phenomenon by repeated
injections of polymeric micelles. Int J Pharm 2012;432:
75–79.
[12] Shimizu T, Ichihara M, Yoshioka Y, et al. Intravenous
administration of polyethylene glycol-coated (PEGylated)
proteins and PEGylated adenovirus elicits an anti-PEG
immunoglobulin M response. Biol Pharm Bull 2012;35:1336–
1342.
[13] Yang Q, Ma Y, Zhao Y, et al. Accelerated drug release and
clearance of PEGylated epirubicin liposomes following
Fig. 6 – The anti-PEG IgM production following intravenous injections of Ragged-NEs. Black square means the serum
obtained from the rat without control; other squares mean the serum obtained from the rat pretreated with C5P5NE,C5P10NE
and P10NE. Each value represents the mean ± SD (n = 3). P values apply to differences between the control and treated
rats.*P < 0.05, **P < 0.01, ***P < 0.001.
35a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 2 ( 2 0 1 7 ) 2 8 – 3 6
repeated injections: a new challenge for sequential low-dose
chemotherapy. Int J Nanomedicine 2013;8:1257–1268.
[14] Ishihara T, Maeda T, Sakamoto H, et al. Evasion of the
Accelerated Blood Clearance Phenomenon by coating of
nanoparticles with various hydrophilic polymers.
Biomacromolecules 2010;11:2700–2706.
[15] Abu Lila AS, Nawata K, Shimizu T, et al. Use of polyglycerol
(PG), instead of polyethylene glycol (PEG), prevents induction
of the accelerated blood clearance phenomenon against
long-circulating liposomes upon repeated administration.
Int J Pharm 2013;456:235–242.
[16] Saadati R, Dadashzadeh S, Abbasian Z, et al. Accelerated
blood clearance of PEGylated PLGA nanoparticles following
repeated injections: effects of polymer dose, PEG coating,
and encapsulated anticancer drug. Pharm Res 2013;30:985–
995.
[17] Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability
and the EPR effect in macromolecular therapeutics. J Control
Release 2000;65:271–284.
[18] Xu H, Wang KQ, Deng YH, et al. Effects of cleavable
PEG-cholesterol derivatives on the accelerated blood
clearance of PEGylated liposomes. Biomaterials
2010;31:4757–4763.
[19] Ishida T, Harada M, Wang XY, et al. Accelerated blood
clearance of PEGylated liposomes following preceding
liposome injection: effects of lipid dose and PEG surface-
density and chain length of the first-dose liposomes. J
Control Release 2005;105:305–317.
[20] Koide H, Asai T, Hatanaka K, et al. Particle size-dependent
triggering of accelerated blood clearance phenomenon. Int J
Pharm 2008;362:197–200.
[21] Kaminskas LM, McLeod VM, Porter CJ, et al. Differences in
colloidal structure of PEGylated nanomaterials dictate the
likelihood of accelerated blood clearance. J Pharm Sci
2011;100:5069–5077.
[22] Hara E, Makino A, Kurihara K, et al. Evasion from accelerated
blood clearance of nanocarrier named as “Lactosome”
induced by excessive administration of Lactosome. Biochim
Biophys Acta 2013;1830:4046–4052.
[23] Taguchi K, Urata Y, Anraku M, et al. Hemoglobin vesicles,
polyethylene glycol (PEG)ylated liposomes developed as a
red blood cell substitute, do not induce the accelerated
blood clearance phenomenon in mice. Drug Metab Dispos
2009;37:2197–2203.
[24] Ishida T, Ichikawa T, Ichihara M, et al. Effect of the
physicochemical properties of initially injected liposomes
on the clearance of subsequently injected PEGylated
liposomes in mice. J Control Release 2004;95:403–412.
[25] Ishida T1, Maeda R, Ichihara M, et al. Accelerated clearance
of PEGylated liposomes in rats after repeated injections. J
Control Release 2003;88:35–42.
[26] Li Y, Liu R, Shi Y, et al. Zwitterionic poly (carboxybetaine)-
based cationic liposomes for effective delivery of small
interfering RNA therapeutics without accelerated blood
clearance phenomenon. Theranostics 2015;5:583–596.
[27] Zhang Q, Deng C, Fu Y, et al. Repeated administration of
hyaluronic acid coated liposomes with improved
pharmacokinetics and reduced immune response. Mol
Pharm 2016;doi:10.1021/acs.molpharmaceut.5b00952.
[28] Mosqueira VC, Legrand P, Gulik A, et al. Relationship
between complement activation, cellular uptake and surface
physicochemical aspects of novel PEG-modified
nanocapsules. Biomaterials 2001;22:2967–2979.
[29] Czajkowsky DM, Shao Z. The human IgM pentamer is a
mushroom-shaped molecule with a flexural bias. Proc Natl
Acad Sci USA 2009;106:14960–14965.
36 a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 2 ( 2 0 1 7 ) 2 8 – 3 6
